ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,475.09
      0.27%
      US Tech 100
      19,202.00
      -0.39%
      Dow Jones
      39,169.52
      0.13%
      Brent Oil
      86.79
      0.30%
      Bitcoin
      62,606.83
      -0.39%
      Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Rubius Therapeutics Inc (RUBY)

      7. Rubius Therapeutics Inc (RUBY) News

      RUBY

      Rubius Therapeutics (RUBY)

      Rubius Therapeutics Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:RUBY
      DateTimeSourceHeadlineSymbolCompany
      10/15/20208:00AMGlobeNewswire Inc.Rubius Therapeutics Announces Preclinical Data Supporting its Lead Clinical Oncology Program, RTX-240, to be Presented at the...NASDAQ:RUBYRubius Therapeutics Inc
      09/29/20204:01PMGlobeNewswire Inc.Rubius Therapeutics to Participate in 7th Annual Jefferies Cell Therapy SummitNASDAQ:RUBYRubius Therapeutics Inc
      09/28/20208:11AMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:RUBYRubius Therapeutics Inc
      09/28/20208:00AMGlobeNewswire Inc.Rubius Therapeutics Appoints Jose Carmona as Chief Financial OfficerNASDAQ:RUBYRubius Therapeutics Inc
      09/08/20204:01PMGlobeNewswire Inc.Rubius Therapeutics to Participate at Upcoming Investor ConferencesNASDAQ:RUBYRubius Therapeutics Inc
      08/10/20208:23AMEdgar (US Regulatory)Quarterly Report (10-q)NASDAQ:RUBYRubius Therapeutics Inc
      08/10/20208:06AMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:RUBYRubius Therapeutics Inc
      08/10/20208:00AMGlobeNewswire Inc.Rubius Therapeutics Reports Second Quarter 2020 Financial Results and Positive Progress Across PipelineNASDAQ:RUBYRubius Therapeutics Inc
      08/03/20204:01PMGlobeNewswire Inc.Rubius Therapeutics to Announce Second Quarter 2020 Financial ResultsNASDAQ:RUBYRubius Therapeutics Inc
      07/07/20208:00AMPR Newswire (US)Flagship Pioneering's Scientists Invent a New Category of Genome Engineering Technology: Gene WritingNASDAQ:RUBYRubius Therapeutics Inc
      06/30/20208:10AMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:RUBYRubius Therapeutics Inc
      06/30/20208:00AMGlobeNewswire Inc.Rubius Therapeutics Provides Update on Clinical Trial Progress for its Lead Oncology Product Candidate RTX-240 and Announces ...NASDAQ:RUBYRubius Therapeutics Inc
      06/22/20208:00AMGlobeNewswire Inc.Rubius Therapeutics Highlights Preclinical Data for RTX-321, a Red Cell Therapeutic™ Oncology Product Candidate for HPV-Pos...NASDAQ:RUBYRubius Therapeutics Inc
      05/28/20208:00AMPR Newswire (US)Flagship Pioneering Bolsters Executive Team with Appointment of Fabrice Chouraqui in Newly Created Dual Role of Flagship CEO-...NASDAQ:RUBYRubius Therapeutics Inc
      05/26/20207:26PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:RUBYRubius Therapeutics Inc
      05/26/20207:25PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:RUBYRubius Therapeutics Inc
      05/26/20207:25PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:RUBYRubius Therapeutics Inc
      05/26/20207:25PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:RUBYRubius Therapeutics Inc
      05/26/20207:25PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:RUBYRubius Therapeutics Inc
      05/26/20207:25PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:RUBYRubius Therapeutics Inc
      05/26/20204:01PMGlobeNewswire Inc.Rubius Therapeutics to Present at Jefferies Virtual 2020 Healthcare ConferenceNASDAQ:RUBYRubius Therapeutics Inc
      05/22/20205:09PMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:RUBYRubius Therapeutics Inc
      05/15/20208:00AMGlobeNewswire Inc.Rubius Therapeutics to Present Preclinical Data for RTX-321, a Red Cell Therapeutic™ Oncology Product Candidate for HPV-Pos...NASDAQ:RUBYRubius Therapeutics Inc
      05/12/20206:00AMGlobeNewswire Inc.Rubius Therapeutics Highlights Preclinical Data for RTX-321, a Red Cell Therapeutic™ Oncology Product Candidate for HPV-Pos...NASDAQ:RUBYRubius Therapeutics Inc
      05/11/20208:22AMEdgar (US Regulatory)Quarterly Report (10-q)NASDAQ:RUBYRubius Therapeutics Inc
      05/11/20208:06AMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:RUBYRubius Therapeutics Inc
      05/11/20208:00AMGlobeNewswire Inc.Rubius Therapeutics Reports First Quarter 2020 Financial Results and Provides Operational UpdateNASDAQ:RUBYRubius Therapeutics Inc
      05/07/20208:00AMGlobeNewswire Inc.Rubius Therapeutics Announces Dosing of First Patient in Phase 1/2 Trial of RTX-240, an Allogeneic Cellular Therapy, for the ...NASDAQ:RUBYRubius Therapeutics Inc
      05/04/20204:01PMGlobeNewswire Inc.Rubius Therapeutics to Announce First Quarter 2020 Financial ResultsNASDAQ:RUBYRubius Therapeutics Inc
      04/29/20208:00AMGlobeNewswire Inc.Rubius Therapeutics Announces Preclinical Data from Red Cell Therapeutic Oncology Programs to be Presented at the ASGCT 23rd ...NASDAQ:RUBYRubius Therapeutics Inc
       Showing the most relevant articles for your search:NASDAQ:RUBY

      Your Recent History

      TSX
      ZFN
      BMO SIA Focused North Am...
      Delayed Upgrade Clock